Sept. 16 (UPI) -- Donepezil, a popular Alzheimer's drug, is linked to a two-fold higher risk of hospital admission for a painful muscle condition than other inhibitors, Canadian Medical Association Journal study found.
Researchers on the study analyzed the 30-day risk of admission to hospital with rhabomyolysis, a painful condition of muscle breakdown, among patients using one of three popular cholinesterase inhibitors -- donepezil, rivastigmine or galantamine -- to manage Alzheimer's and symptoms of other dementias.